Get the Stockscreener App
1.42
3.40%
-0.05
After Hours:
1.42
Can-Fite Biopharma Ltd ADR stock is traded at $1.42, with a volume of 39,321.
It is down -3.40% in the last 24 hours and down -18.86% over the past month.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$1.47
Open:
$1.47
24h Volume:
39,321
Relative Volume:
0.09
Market Cap:
$8.66M
Revenue:
$743.00K
Net Income/Loss:
$-7.63M
P/E Ratio:
-0.4733
EPS:
-3
Net Cash Flow:
-
1W Performance:
-8.39%
1M Performance:
-18.86%
6M Performance:
-46.01%
1Y Performance:
-30.05%
1-Day Range:
$1.4061
$1.48
1-Week Range:
$1.38
$1.5499
52-Week Range:
$1.29
$4.69
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADR
Sector
Industry
Phone
972 3 924 1114
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
1.42 | 8.66M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-17 | Initiated | Maxim Group | Buy |
| Oct-19-16 | Resumed | ROTH Capital | Buy |
| Aug-29-16 | Resumed | Rodman & Renshaw | Buy |
| Nov-30-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-31-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-30-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-29-14 | Reiterated | ROTH Capital | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
View All
Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 - GlobeNewswire Inc.
USC Law Launches New Online Certificate in Dispute Resolution - Business Wire
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions - Business Wire
Cronos Group Inc (NASDAQ: CRON) Could Slash -12.75% Soon - Stocks Register
Commercial Metals Co (NYSE: CMC) Could Slash -1.03% Soon - Stocks Register
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Reckitt Benckiser Group PLC (OTC: RBGLY) - Business Wire
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com India
Can-Fite secures Australian patent for obesity treatment - Investing.com
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of WeRide Inc. - Business Wire
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India
Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is CANF’s price-to-sales ratio telling us about the company’s value? - US Post News
Taking on analysts’ expectations and winning: Can-Fite Biopharma Ltd ADR (CANF) - SETE News
Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex
CANF (Can-Fite Biopharma Ltd ADR) has impressive results - US Post News
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Can-Fite Announces ADS Ratio Change - Business Wire
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
NOVONIX to Commence Trading on Nasdaq through Level II ADR Program - Business Wire
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire
Global Metal Casting Market 2020-2024 | Evolving Opportunities with Acast and Alcast Co. | Technavio - Business Wire
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
letgo Raises $100 Million in Series A Funding from Naspers - Business Wire
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC
Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):